N/A
N=55
Progression of Airway Obstruction in Childhood Asthma
Asthma
Bottom Line
View on ClinicalTrials.gov: NCT00873873 ↗Enrolled (actual)
55
Serious AEs
0.0%
Results posted
Jan 2012
Primary outcome: Primary: Airway Wall Thickness — 1.5; 1.5; 1.4; 1.6 mm — p=0.2
Study Design & Population
- Study type
- Observational
- Phase
- N/A
- Interventions
- —
- Age
- Pediatric, Adult · 16+ yrs
- Sex
- All
- Sponsor
- National Jewish Health
- Primary completion
- Jun 2011
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Airway Wall Thickness |
1.5; 1.5; 1.4; 1.6 | 0.2 |
| SECONDARY Protease/Antiprotease |
34.1; 29.3; 9.9; 12.1 | — |
Summary
Distinct patterns of loss in pulmonary function were identified in children with mild to moderate asthma participating in a 10-year observation period during the NHLBI Childhood Asthma Management Program. This loss in pulmonary function is likely related to ongoing inflammation unresponsive to current therapy. This study will measure indicators of airway inflammation which are associated with structural and physiologic changes in the lung and provide insight into mechanisms of asthma progression in adolescence and early adulthood.
Eligibility Criteria
Inclusion Criteria
- Must be enrolled in the CAMPCS/3 study; individuals enrolled in this study will represent four different patterns of asthma progression, as defined by forced expiratory volume in 1 second (FEV1)/forced vital capacity (FVC) levels
Exclusion Criteria
- Unwilling to comply with study procedures
- Physical state does not allow the study procedures to be performed (e.g., low pulmonary function for induced sputum, pregnancy for computerized tomography [CT] scan)
Data sourced from ClinicalTrials.gov (NCT00873873). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.